Shenzhen Neptunus Bioengineering Co Ltd (000078) - Total Assets
Based on the latest financial reports, Shenzhen Neptunus Bioengineering Co Ltd (000078) holds total assets worth CN¥25.73 Billion CNY (≈ $3.77 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shenzhen Neptunus Bioengineering Co Ltd - Total Assets Trend (1995–2025)
This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see how much is Shenzhen Neptunus Bioengineering Co Ltd worth for the company's overall valuation and market capitalisation.
Shenzhen Neptunus Bioengineering Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Shenzhen Neptunus Bioengineering Co Ltd's total assets of CN¥25.73 Billion consist of 90.1% current assets and 9.9% non-current assets. Review 000078 current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.3% |
| Accounts Receivable | CN¥13.20 Billion | 50.1% |
| Inventory | CN¥3.20 Billion | 12.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥442.20 Million | 1.7% |
| Goodwill | CN¥241.41 Million | 0.9% |
Asset Composition Trend (1995–2025)
This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 000078 share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenzhen Neptunus Bioengineering Co Ltd's current assets represent 90.1% of total assets in 2025, an increase from 57.4% in 1995.
- Cash Position: Cash and equivalents constituted 11.3% of total assets in 2025, down from 13.0% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 18.0% in 1995.
- Asset Diversification: The largest asset category is accounts receivable at 50.1% of total assets.
Shenzhen Neptunus Bioengineering Co Ltd Competitors by Total Assets
Key competitors of Shenzhen Neptunus Bioengineering Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Shenzhen Neptunus Bioengineering Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.00 | 1.02 | 1.04 |
| Quick Ratio | 0.87 | 0.89 | 0.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥10.37 Million | CN¥553.93 Million | CN¥1.40 Billion |
Shenzhen Neptunus Bioengineering Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shenzhen Neptunus Bioengineering Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.75 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -8.6% |
| Total Assets | CN¥26.33 Billion |
| Market Capitalization | $585.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shenzhen Neptunus Bioengineering Co Ltd's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shenzhen Neptunus Bioengineering Co Ltd's assets decreased by 8.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shenzhen Neptunus Bioengineering Co Ltd (1995–2025)
The table below shows the annual total assets of Shenzhen Neptunus Bioengineering Co Ltd from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥26.33 Billion ≈ $3.85 Billion |
-8.56% |
| 2024-12-31 | CN¥28.80 Billion ≈ $4.21 Billion |
-10.85% |
| 2023-12-31 | CN¥32.30 Billion ≈ $4.73 Billion |
-10.89% |
| 2022-12-31 | CN¥36.25 Billion ≈ $5.30 Billion |
-3.59% |
| 2021-12-31 | CN¥37.60 Billion ≈ $5.50 Billion |
-5.33% |
| 2020-12-31 | CN¥39.72 Billion ≈ $5.81 Billion |
-3.52% |
| 2019-12-31 | CN¥41.17 Billion ≈ $6.02 Billion |
+0.10% |
| 2018-12-31 | CN¥41.13 Billion ≈ $6.02 Billion |
+33.25% |
| 2017-12-31 | CN¥30.86 Billion ≈ $4.52 Billion |
+85.24% |
| 2016-12-31 | CN¥16.66 Billion ≈ $2.44 Billion |
+30.55% |
| 2015-12-31 | CN¥12.76 Billion ≈ $1.87 Billion |
+32.50% |
| 2014-12-31 | CN¥9.63 Billion ≈ $1.41 Billion |
+20.11% |
| 2013-12-31 | CN¥8.02 Billion ≈ $1.17 Billion |
+36.77% |
| 2012-12-31 | CN¥5.86 Billion ≈ $858.02 Million |
+21.26% |
| 2011-12-31 | CN¥4.84 Billion ≈ $707.56 Million |
+16.58% |
| 2010-12-31 | CN¥4.15 Billion ≈ $606.95 Million |
+31.06% |
| 2009-12-31 | CN¥3.16 Billion ≈ $463.10 Million |
+13.94% |
| 2008-12-31 | CN¥2.78 Billion ≈ $406.44 Million |
-11.02% |
| 2007-12-31 | CN¥3.12 Billion ≈ $456.79 Million |
-11.38% |
| 2006-12-31 | CN¥3.52 Billion ≈ $515.44 Million |
-11.63% |
| 2005-12-31 | CN¥3.99 Billion ≈ $583.30 Million |
+6.93% |
| 2004-12-31 | CN¥3.73 Billion ≈ $545.50 Million |
-7.49% |
| 2003-12-31 | CN¥4.03 Billion ≈ $589.64 Million |
+17.50% |
| 2002-12-31 | CN¥3.43 Billion ≈ $501.82 Million |
+12.67% |
| 2001-12-31 | CN¥3.04 Billion ≈ $445.38 Million |
+248.92% |
| 2000-12-31 | CN¥872.30 Million ≈ $127.64 Million |
+35.81% |
| 1999-12-31 | CN¥642.28 Million ≈ $93.99 Million |
+179.29% |
| 1998-12-31 | CN¥229.97 Million ≈ $33.65 Million |
+57.92% |
| 1997-12-31 | CN¥145.63 Million ≈ $21.31 Million |
+18.39% |
| 1996-12-31 | CN¥123.00 Million ≈ $18.00 Million |
+49.04% |
| 1995-12-31 | CN¥82.53 Million ≈ $12.08 Million |
-- |
About Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, manufacturing, and distribution of pharmaceuticals in China. The company also provides distribution of medical devices, and other medical supplies, as well as related value-added services. It serves medical institutions, drug retailers, and distributors. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 19… Read more